secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001493152-23-008250
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech FY2022 revenue $45.8M (+90% YoY); net loss $8.1M
---------------------------------------------------------------

- Net revenue $45.8M vs $24.1M in 2021, a 90% increase; gross margin 86% vs 90%.
- Net loss $8.1M vs $8.0M in 2021; SG&A expenses rose to $46.0M from $28.1M.
- CellerateRX sold in over 700 facilities across 29 states; generated >$5M revenue in a single month.
- Entered partnership with InfuSystem for wound care; filed 510(k) for BIASURGE and Precision Healing Imager.
- Entered ATM sales agreement with Cantor Fitzgerald for stock offerings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/0001493152-23-008250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315223008250/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-008250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer